DERMATOLOGY UPDATE SPONSOR Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd. is the world’s fourth largest specialty generic pharmaceutical company. A vertically integrated business and a skilled team enables us to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Our global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7% of annual revenues in R&D.
We are pleased to have expanded into Canada, establishing a Sun Pharma Canada Inc. affiliate. We have launched two brands, tildrakizumab (PrILUMYA®️), an IL-23 p19inhibitor for moderate-to-severe plaque psoriasis, and a hedgehog inhibitor sonidegib (ODOMZO®), for locally advanced basal cell carcinoma. Our goal is to demonstrate our commitment in Dermatology and working in close partnership with the Canadian Healthcare System and Patients.